Aldeyra Therapeutics (ALDX) Expected to Announce Earnings on Thursday

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Aldeyra Therapeutics to post earnings of ($0.25) per share and revenue of ($0.80) million for the quarter.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.30). On average, analysts expect Aldeyra Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aldeyra Therapeutics Price Performance

Shares of ALDX stock traded down $0.09 on Tuesday, reaching $2.68. 249,575 shares of the company were exchanged, compared to its average volume of 716,790. The business has a 50-day moving average price of $4.68 and a 200 day moving average price of $5.03. Aldeyra Therapeutics has a 1 year low of $1.14 and a 1 year high of $7.20. The company has a market cap of $159.72 million, a price-to-earnings ratio of -2.85 and a beta of 0.94. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ALDX shares. BTIG Research lowered their target price on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Monday, April 7th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Friday, April 4th.

Insider Activity at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. The trade was a 36.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.50% of the stock is owned by insiders.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.